Holen Sie sich die Stockscreener-App
35.60
4.35%
-1.62
Handel nachbörslich:
35.45
-0.15
-0.42%
Schlusskurs vom Vortag:
$37.22
Offen:
$37.21
24-Stunden-Volumen:
2.11M
Relative Volume:
0.96
Marktkapitalisierung:
$2.96B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-12.71
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
+3.94%
1M Leistung:
-8.27%
6M Leistung:
-24.01%
1J Leistung:
-36.10%
1-Tages-Spanne:
$35.38
$38.64
1-Wochen-Bereich:
$34.12
$38.64
52-Wochen-Spanne:
$30.04
$67.88
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
35.60 | 2.96B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Barclays Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $42.00 - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Benjamin Edwards Inc. - MarketBeat
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - MSN
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks - MSN
2 Biotech Stocks That Are Screaming Buys in May - Yahoo Finance
Chardan Capital Issues Optimistic Forecast for CRSP Earnings - MarketBeat
Equities Analysts Set Expectations for CRSP Q2 Earnings - MarketBeat
Q2 EPS Estimate for CRISPR Therapeutics Raised by Analyst - MarketBeat
Needham & Company LLC Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price - MarketBeat
CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Wednesday - MarketBeat
Chardan Capital Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price - MarketBeat
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? - AOL.com
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? - The Motley Fool
CRISPR Therapeutics (CRSP) to Release Earnings on Wednesday - Defense World
William Blair Expects Lower Earnings for CRISPR Therapeutics - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for CRSP Earnings - MarketBeat
(CRSP) Investment Report - news.stocktradersdaily.com
Bridgefront Capital LLC Invests $680,000 in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Illinois Tool Works, Wynn Resorts, Agree Realty, Crispr Therapeutics, Super Micro Computer: Trending by Analysts - MSN
Dimensional Fund Advisors LP Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Chardan Capital Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $82.00 - Defense World
Crispr Therapeutics (CRSP) Price Target Reduced by Barclays to $42 | CRSP Stock News - GuruFocus
CRISPR Therapeutics (CRSP) Downgraded Amid Market Challenges - GuruFocus
CRISPR Therapeutics (CRSP) Price Target Lowered by Barclays | CRSP Stock News - GuruFocus
Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines - Seeking Alpha
Baker BROS. Advisors LP Has $51.48 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NasdaqGM:CRSP) Q1 2025 Revenue Increases 71% to US$1 Million - Yahoo Finance
CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results - insights.citeline.com
CRISPR Therapeutics (CRSP): Goldman Sachs Lowers Price Target to $47 | CRSP Stock News - GuruFocus
June 27th Options Now Available For CRISPR Therapeutics - Nasdaq
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet - Yahoo Finance
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade) - Seeking Alpha
Promising Developments and Pipeline Expansion at Crispr Therapeutics AG Support Buy Rating - TipRanks
Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRSP: Needham Maintains Buy Rating Despite Target Price Reductio - GuruFocus
Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst - Benzinga
CRSP Sees Price Target Adjustment by BofA Amid Key Updates | CRS - GuruFocus
Crispr Therapeutics price target lowered to $79 from $80 at BofA - TipRanks
CRSP Sees Price Target Adjustment by BofA Amid Key Updates | CRSP Stock News - GuruFocus
CRSP: Needham Maintains Buy Rating Despite Target Price Reduction | CRSP Stock News - GuruFocus
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results - Benzinga
CRSP Stock: Analyst Maintains Buy Rating, Lowers Price Target | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Trial Results and Strong Financial Position Support Buy Rating - TipRanks
Crispr Therapeutics AG: Strong Buy Rating Backed by Promising Clinical Data and Strategic Collaborations - TipRanks
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates - MSN
Crispr Therapeutics (CRSP) Upgraded to Buy by Clear Street Analyst | CRSP Stock News - GuruFocus
Crispr Therapeutics upgraded to Buy from Hold at Clear Street - TipRanks
Crispr Therapeutics AG: Balancing Growth Potential with Profitability Challenges – Hold Rating - TipRanks
NKureCRISPR Therapeutics partner to develop off-the-shelf CAR-T therapy - BusinessLine
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):